<code id='E34EBB4052'></code><style id='E34EBB4052'></style>

<acronym id='E34EBB4052'></acronym>

<center id='E34EBB4052'><center id='E34EBB4052'><tfoot id='E34EBB4052'></tfoot></center><abbr id='E34EBB4052'><dir id='E34EBB4052'><tfoot id='E34EBB4052'></tfoot><noframes id='E34EBB4052'>

<optgroup id='E34EBB4052'><strike id='E34EBB4052'><sup id='E34EBB4052'></sup></strike><code id='E34EBB4052'></code></optgroup>

<b id='E34EBB4052'><label id='E34EBB4052'><select id='E34EBB4052'><dt id='E34EBB4052'><span id='E34EBB4052'></span></dt></select></label></b><u id='E34EBB4052'></u>

~~<i id='E34EBB4052'><strike id='E34EBB4052'><tt id='E34EBB4052'><pre id='E34EBB4052'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

hotspot

author：knowledge 2025-09-27 10:58:57 Page View：9267

Merck — Kena Betancur/Getty Images

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

advertisement

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn
Next article： Medical leaders decry Supreme Court decision on affirmative action

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

MollyFerguson/STATThisweek,anencouragingturnaroundforOcularTherapeutix,achatwithAlnylam’sCEOdefendin

Medical records are filled with copy

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

The Harvard botanist who searched for psychedelics in the Amazon

RichardEvansSchultesintheCerroCampanamountainsinColombia,inJune1943.TheEstateofRichardEvansSchultes/

read more